National and Global Asthma Management Guiding Principles 2023

Kenneth Miller MEd, MSRT, RRT-ACCS, AE-C, FAARC

Learning Objectives

Describe	Define	Review	
Describe the evolution of asthma over the past several decades	Define the scientific methodology utilization in asthma management	Review the current recommends germane to asthma clinical management	

Asthma Epidemiology

262 million individuals are diagnosed with asthma

Mortality rate remains relatively low at approximately 1%

However, the burden and cost of treating and managing asthma remains very high

In the United States the cost of indirect and direct management exceeds 300 billion dollars

Cost exceeds 650 billion dollars globally

Two Primary Asthma Resources

National Asthma Education and Prevention Program (NAEPP)	• 1989
Asthma Report (GINA)	• 1993
The goal of these governing bodies are to:	 Increase the awareness of asthma Recognize signs and symptoms of asthma Ensure effective asthma control Enhance the quality of life of people with asthma

The Evolution of Asthma Management

- 1960-1970s
 - Focus was on the treatment and prevention of bronchospasm
 - Rescue beta-agonist
- 1980-1990s
 - Focus shifted to avoidance of asthma triggering
 - Control chronic inflammation
 - Inhaled corticosteroids
- Currently
 - Viewed as a heterogenous disease
 - Specially individualized designed action plans
 - Use of biological therapies

Scientific Methodology

Utilized objective and standardized approaches to formulate recommendations per evidence-based reviews

Are composed of leading asthma management experts Work in collaboration with other committee experts

• ATS, ACCP, ERS

Developments a need assessment profile based on recommends and current evidence

Conducts quality and research follow up based on recommendations

Review of Current Literature

- Use of inhaled corticoid steroids in children<6 years old
- Intermittent maintenance and relief therapy
- Exercise pretreatment
- Short term Increase in inhaled steroids
- Long-acting Muscarinic Antagonists
- Exhaled Nitric Oxide as a monitoring assessment in asthma
- Indoor Allergen Mitigation
- Immunology therapy
- Bronchial Thermoplasty
- COVID-19 and Asthma

Intermittent Inhaled Corticosteroids in Children<6 yrs. Old

- Asthma effects about 7% of all children
- Asthma is often difficult to from other childhood diseases
 - Bronchiolitis
 - Foreign body aspiration
 - Tracheal malacia
 - IRDS
- Asthma diagnosis should be confirmed utilizing a predictive index
 - Bronchodilator response
 - Eosinophilia
 - Family history
- The recommendation is if there is recurrent wheezing, episodes > 3 times, a short course of inhaled steroids should be administered (7-14 days)
 - In conjunction with a PRN SABA

Intermittent Maintenance and Relief Therapy

- Daily low dosage ICS and PRN SABA (Step2)
- <mark>SMART</mark>
 - Includes an ICS and LABA as a single maintenance and relief therapy
- Alternative therapies include
 - Leukotriene receptor antagonists
 - Cromolyn
 - Theophylline



- at 20-min intervals as needed. Short course of oral systemic corticosteroids may be needed.
- Use of SABA >2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control and the need to step up treatment.

Adults & adolescents 12+ years

Personalized asthma management Assess, Adjust, Review for individual patient needs

Confirmation of diagnosis if necessary Symptom control & modifiable risk factors (including lung function) Comorbidities Inhaler technique & adherence Patient preferences and goals

Treatment of modifiable risk factors and comorbidities Non-pharmacological strategies Asthma medications (adjust down/up/between tracks) Education & skills training

Medium/high

ICS-LABA

dose maintenance

CONTROLLER and PREFERRED RELIEVER

(Track 1). Using ICS-formoterol as reliever reduces the risk of exacerbations compared with using a SABA reliever

STEPS 1 – 2 As-needed low dose ICS-formoterol	STEP 3 Low dose maintenance ICS-formoterol	STEP 4 Medium dose maintenance ICS-formoterol	Add-on LAMA Refer for phenotypic assessment ± anti-IgE, anti-IL5/5R, anti-IL4R Consider high dose ICS-formoterol
RELIE	VER: As-needed low-dos	se ICS-formoterol	
		STEP 4	STEP 5

STEP 3

Low dose

maintenance

ASSES

ADJUST

REVIEW

Symptoms Exacerbations Side-effects

Lung function

Patient satisfaction

STEP 2

STED 1

CONTROLLER and **ALTERNATIVE RELIEVER**

(Track 2). Before considering a regimen with SABA reliever.	Take ICS whenever SABA taken	maintenance ICS	ICS-LABA		
check if the patient is likely to be adherent with daily controller		RELIEVER: As-needed short-acting β2-agonist			
Other controller options for either track		Low dose ICS whenever SABA taken, or daily LTRA, or add HDM SLIT	Medium dose ICS, or add LTRA, or add HDM SLIT	Add LAMA or LTRA or HDM SLIT, or switch to high dose ICS	

Add azithromycin (adults) or LTRA: add low dose OCS but consider side-effects

Refer for phenotypic

assessment ± anti-IgE,

anti-IL5/5R, anti-IL4R

Consider high dose

ICS-LABA

STEP 5

Exercise Pretreatment with Single Maintenance and Relief Therapy

90% of asthmatic experience exercised induced-asthma

Recommendation is to utilize a low dose ICS with prn SABA

No benefit in adding a LABA in this group

Short-Term Increase in Daily ICS

Considering doubling or tripling ICS dosage during asthma exacerbation

7-14 days dosing

More studies need to be done to determine an exact dosing regime

Long-Acting Muscarinic Antagonists

- Asthma is caused by airway inflammation, hypersecretion, and smooth muscle contraction
- The vagal nerve that controls the neurotransmitters and secretion acetylcholine in the submucosal gland, smooth muscle and epithelial cells that results in bronchospasm and hypersecretion
- LAMA block the release of acetylcholine and thus prevent bronchospasm and hypersecretion
- Sometimes recommend for asthma management
- May be useful as an add on therapy in poorly controlled asthma with other established medications.
- Should be NEVER used as a stand-alone asthmatic drug regime



Exhaled Nitric Oxide

Non-invasive way to assess and monitor airway inflammation in asthma

FENO>50ppmin non-smokers, is associated with eosinophilic airway inflammation

FENO monitoring has become the standard to monitor ICS effectiveness

The recommendation is that FENO is useful to monitor asthma medication effectives or patient compliance

FENO is not useful in diagnosis or predicting the development of Asthma. PFTs are the standard in diagnosis assessment.



Indoor Allergen Mitigation

Control of environment factors is an integral part of asthma management

Common indoor allergens include:

- Dust mites
- Pet dander
- Molds
- Pest feces

Allergen mitigation include:

- Impermeable pillow and mattress covers
- Pest eradication and management
- Animal dander sensitivity



COMMON INDOOR ALLERGIES

THAT MAY BE MAKING YOU FEEL SICK



10 Ways to Curb Hidden Allergens at Home



Immunotherapy

- About 40% of all asthmatics suffer with allergic rhinitis
- Asthma exacerbations may be caused by exposure to a specific allergen in a specific season(ragweed)
- Recommendation is that immunotherapy as a treatment option if the allergen plays a role in asthma exacerbations
- Can be administered by subcutaneous injection or sublingually
- No studies that demonstrate
- No studies has demonstrated a reduction in:
 - Provider visits
 - Improvement in quality of life
 - ER visits

	Treatment A		Treatment B	
How the treatment is administered	Infusion under skin at home		Infusion into vein at clinic	
How many needle sticks	4 needle sticks per tr 4 needle sticks per	eatment month	2 needle sticks per tr 8 needle sticks per	eatment month
How often you take the treatment	Every 4 weeks		Once per week	<pre></pre>
Total time per treatment	Administration time:	5 hours	Administration time:	1 hour
	Headache & drowsiness:	12 hours	Headache & drowsiness:	None
	Total time: Time per month:	17 hours 17 hours	Total time: Time per month:	1 hour 4 hours
Vhich would you	Treatment A		Treatment	A
hoose, if these vere the only ptions available?	0		0	

Bronchial Thermoplasty

- This bronchoscopy therapy delivers local radiofrequency to the airways
- This causes modulation of the extracellular matrix formed by inflammation
- Currently the GINA and NAEPP panels can not recommend this intervention for refractory asthma secondary to small benefits compare to the potential side effects
 - Infection
 - Bleeding
 - Atelectasis
 - No long-term benefit> 5 yrs.



Airways Before and After Bronchial Thermoplasty Treatment

Airway of Person without Asthma



Airway of Person with Severe Asthma



-----More airway muscle causes airway to narrow ------ This is the area where Alair applies heat to the airway wall during BT treatment

Airway of Person with Severe Asthma after Treatment



----- Reduced airway muscle after BT treatment

After BT, the inside airway wall and other tissue heals, but airway muscle is reduced

COVID-19 and Asthma

- Respiratory viruses are a common trigger that can cause an exacerbation
- Asthmatic who are well controlled had no greater risk of acquiring COVID than non-asthmatic
- No increased risk of hospitalization or death
- Those that were a risk included
 - Uncontrolled asthma
 - Diabetics
 - Cardiovascular disease
 - Obesity
 - Non vaccinated
 - Vaccination is recommended

Conclusion

- Both NAEPP and GINA are valuable resources that make recommendations on best asthma management practices
- Health care provides need to keep aware of the changing asthma management recommendations
- Asthma management is evolutionary and will continue to adapt based on new evidence

References

- Enilari O, Sinha S. The Global Impact of Asthma in Adult Populations. Ann Glob Health 2019;85(1):2
- National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program (NAEPP). https://www.nhlbi.nih.gov/science/ national-asthma-educationand-prevention-program-naepp. Accessed February 21, 2022.
- Global Initiative for Asthma. About us. https://ginasthma.org/aboutus/. Accessed February 21, 2022.